CoChat

Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma

Hungria, Vania, Robak, Pawel, Hus, Marek, Zherebtsova, Vera, Ward, Christopher, Ho, P. Joy, Ribas de Almeida, Ana Carolina, Hajek, Roman, Kim, Kihyun, Grosicki, Sebastian, Sia, Hanlon, Bryant, Adam, Pitombeira de Lacerda, Marcelo, Aparecida Martinez, Gracia, Sureda Balarí, Anna Maria, Sandhu, Irwindeep, Cerchione, Claudio, Ganly, Peter, Dimopoulos, Meletios, Fu, Chengcheng, Garg, Mamta, Abdallah, Al-Ola, Oriol, Albert, Gatt, Moshe E., Cavo, Michele, Rifkin, Robert, Fujisaki, Tomoaki, Mielnik, Michał, Pirooz, Nick, McKeown, Astrid, McNamara, Simon, Zhou, Xiangdong, Nichols, Maureen, Lewis, Eric, Rogers, Rachel, Baig, Hena, Eccersley, Lydia, Roy-Ghanta, Sumita, Opalinska, Joanna, Mateos, María-Victoria · 2024 · New England Journal of Medicine

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Belantamab mafodotin had single-agent activity in patients with relapsed or refractory multiple myeloma, a finding that supports further evaluation of the agent in combination with standard-care therapies. METHODS: In this phase 3, open-label, randomized trial, we evaluated belantamab mafodotin, bortezomib, and dexamethasone (BVd), as compared with daratumumab, bortezomib, and dexamethasone (DVd), in patients who had progression of multiple myeloma after at least one line of therapy. The primary end point was progression-free survival. Key secondary end points were overall survival, response duration, and minimal residual disease (MRD)-negative status. RESULTS: In total, 494 patients were randomly assigned to receive BVd (243 patients) or DVd (251 patients). At a median follow-up of 28.2 months (range, 0.1 to 40.0), median progression-free survival was 36.6 months (95% confidence interval [CI], 28.4 to not reached) in the BVd group and 13.4 months (95% CI, 11.1 to 17.5) in the DVd group (hazard ratio for disease progression or death, 0.41; 95% CI, 0.31 to 0.53; P<0.001). Overall survival at 18 months was 84% in the BVd group and 73% in the DVd group. An analysis of the restricted mean response duration favored BVd over DVd (P<0.001). A complete response or better plus MRD-negative status occurred in 25% of the patients in the BVd group and 10% of those in the DVd group. Grade 3 or higher adverse events occurred in 95% of the patients in the BVd group and 78% of those in the DVd group. Ocular events were more common in the BVd group than in the DVd group (79% vs. 29%); such events were managed with dose modifications, and events of worsening visual acuity mostly resolved. CONCLUSIONS: As compared with DVd therapy, BVd therapy conferred a significant benefit with respect to progression-free survival among patients who had relapsed or refractory multiple myeloma after at least one line of therapy. Most patients had grade 3 or higher adverse events. (Funded by GSK; DREAMM-7 ClinicalTrials.gov number, NCT04246047; EudraCT number, 2018-003993-29.).

Overview

Integrity signals

Registry

Crossref · 10.1056/nejmoa2405090

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 28 references

Cited by

See all 209

Metadata

Authors
Hungria, V., Robak, P., Hus, M., Zherebtsova, V., Ward, C., Ho, P. J., Ribas de Almeida, A. C., Hajek, R., Kim, K., Grosicki, S., Sia, H., Bryant, A., Pitombeira de Lacerda, M., Aparecida Martinez, G., Sureda Balarí, A. M., Sandhu, I., Cerchione, C., Ganly, P., Dimopoulos, M., Fu, C., Garg, M., Abdallah, A.-O., Oriol, A., Gatt, M. E., Cavo, M., Rifkin, R., Fujisaki, T., Mielnik, M., Pirooz, N., McKeown, A., McNamara, S., Zhou, X., Nichols, M., Lewis, E., Rogers, R., Baig, H., Eccersley, L., Roy-Ghanta, S., Opalinska, J., & Mateos, M.-V.
Affiliations
  • From Clinica São Germano (V.H.) and Hospital das Clínicas and Instituto do Câncer do Estado de São Paulo, Universidade de São Paulo (G.A.M.), São Paulo, Centro de Pesquisa e Ensino em Saúde de Santa Catarin, Florianópolis (A.C.R.A.), and Universidade da Região de Joinville and Centro de Hematologia e Oncologia, Joinville (M.P.L.) — all in Brazil; Medical University of Lodz, Lodz (P.R.), Medical University of Lublin, Lublin (M.H., M.M.), and the Medical University of Silesia, Katowice (S.G.) — all in Poland; Gorodskaya Klinicheskaya Bol’nitsa Imeni Saint Petersburg Botkina, Moscow (V.Z.); the Royal North Shore Hospital (C.W.) and Liverpool Hospital (A.B.), Sydney, Royal Prince Alfred Hospital and University of Sydney, Camperdown, NSW (P.J.H.), and Pindara Private Hospital, Gold Coast, QLD (H.S.) — all in Australia; the Department of Hematooncology, University Hospital Ostrava, and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic (R.H.); Sungkyunkwan University and Samsung Medical Center, ...
  • Medical University of Lublin (PL)
Venue
New England Journal of Medicine
Published
2024-08-01
Volume
391
Issue
5
Pages
393-407
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W4399257301
Cited by
199
References
28
Citations by year
2026: 83 · 2025: 96 · 2024: 20
FWCI
61.73
Type
journal article
Language
en
Open access
closed
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • DIGITAL.CSIC (Spanish National Research Council (CSIC)) (acceptedVersion)
  • Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
Funders
GlaxoSmithKline
Topics
  • Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
  • Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
  • Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
Keywords
belantamab mafodotin, daratumumab, bortezomib, dexamethasone, relapsed/refractory multiple myeloma, progression-free survival, overall survival, minimal residual disease, ocular adverse effects, visual acuity, combination therapy, monoclonal antibody-drug conjugate, proteasome inhibitors, immunomodulators
MeSH terms
Bortezomib, Progression-Free Survival, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Female, Humans, Male, Middle Aged, Multiple Myeloma, Survival Analysis, Neoplasm, Residual, Disease Progression, Kaplan-Meier Estimate, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma. https://app.cochat.ai/papers/10.1056/nejmoa2405090
The paper
Hungria, V., Robak, P., Hus, M., Zherebtsova, V., Ward, C., Ho, P. J., Ribas de Almeida, A. C., Hajek, R., Kim, K., Grosicki, S., Sia, H., Bryant, A., Pitombeira de Lacerda, M., Aparecida Martinez, G., Sureda Balarí, A. M., Sandhu, I., Cerchione, C., Ganly, P., Dimopoulos, M., . . . Mateos, M.-V. (2024). Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2405090

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.